Reactogenicity, safety and disease flares following BNT162b2 mRNA COVID-19 vaccine in patients with chronic immune-inflammatory arthritis treated with biological and targeted synthetic disease-modifying anti-rheumatic drugs

CONCLUSIONS: The safety of mRNA COVID-19 vaccination in arthritis patients on treatment with b/tsDMARDs is reassuring. In a regimen of peri-vaccine drug interruption, transient flares of the disease more commonly occur in association with active arthritis and use of shorter half-life drugs. Most flares do not require treatment escalation or change.PMID:36135948 | DOI:10.55563/clinexprheumatol/0ltj1i

Source: Clinical and Experimental Rheumatology - September 22, 2022 Category: Rheumatology Authors: Ludovico De Stefano Silvia Balduzzi Laura Bogliolo Bernardo D'Onofrio Michele di Lernia Eleonora Mauric Alessandra Milanesi Fabio Brandolino Clarissa Rocca Sofia Chiricolo Antonio Manzo Carlomaurizio Montecucco Serena Bugatti Source Type: research